Targeted therapy for metastatic renal cell carcinoma
Seven small molecular weight targeted agents have been approved for the treatment of metastatic renal cell carcinoma (mRCC), includ-ing the humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (used in combination with interferon [IFN]-a); the multi-targeted recep...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26975 |